Company Overview - Esperion Therapeutics, Inc. is a commercial stage biopharmaceutical company focused on developing new medicines for unmet patient needs, particularly in cardiovascular disease [3] - The company has developed the only FDA-approved oral, once-daily, non-statin medications for patients with elevated low-density lipoprotein cholesterol (LDL-C) [3] - Esperion's medications are supported by the CLEAR Cardiovascular Outcomes Trial, which involved nearly 14,000 patients [3] Upcoming Financial Results - Esperion will report its second quarter 2025 financial results before the market opens on August 5, 2025 [1] - Following the financial results release, management will host a webcast at 8:00 a.m. ET to discuss the results and provide business updates [1] Business Development - The company is advancing its next-generation program focused on developing ATP citrate lyase inhibitors (ACLYi), leveraging new insights into drug design [3] - Esperion is evolving into a leading global biopharmaceutical company through commercial execution, international partnerships, and collaborations [4]

Core Insights - Esperion has appointed Robert E. Hoffman as an independent director and Chairperson of the Audit Committee, effective immediately and May 29, 2025, respectively [1][2] - Nicole Vitullo and Antonio M. Gotto, Jr., M.D., D. Phil. will step down from the board of directors on June 1, 2025 [1] Company Developments - Robert E. Hoffman brings extensive experience in the biopharmaceutical sector, having held leadership roles in various companies, which is expected to benefit Esperion's commercialization efforts and pipeline expansion [2][4] - The company is focused on developing next-generation ATP citrate lyase inhibitors (ACLYi) to address unmet cardiometabolic needs [5][6] Leadership Background - Mr. Hoffman has previously served as President, CEO, and CFO of Kintara Therapeutics, and held senior financial roles at Heron Therapeutics and Arena Pharmaceuticals, contributing to his expertise in commercialization [2][4] - He is also involved with several other life sciences companies and has served on various financial committees, enhancing his leadership credentials [3][4] Company Overview - Esperion is a commercial-stage biopharmaceutical company that has developed the only FDA-approved oral, once-daily, non-statin medications for patients at risk for cardiovascular disease [5] - The company aims to evolve into a leading global biopharmaceutical entity through commercial execution and international partnerships [6]